Search This Blog

Monday, September 21, 2026

Amneal FDA approval, begins U.S. launch of generic lanreotide injection Somatuline Depot alternative

 


  • Lanreotide injection is CGT-designated, as specified in Amneal’s announcement of the FDA approval and U.S. launch.
  • Immediate U.S. launch of lanreotide injection expands Amneal’s complex injectables portfolio with a generic to Somatuline Depot.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)